Your email has been successfully added to our mailing list.

×
0.014957264957265 0.014957264957265 0.014957264957265 0.014957264957265 -0.0352564102564101 -0.0576923076923076 -0.0170940170940169 -0.0422863247863247
Stock impact report

Aptevo Therapeutics Begins Patient Dosing in Phase 2 Clinical Trial of Otlertuzumab in Peripheral T-Cell Lymphoma

Aptevo Therapeutics Inc. (APVO) 
Last aptevo therapeutics inc. earnings: 8/9 09:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.aptevotherapeutics.com/investor-overview
Company Research Source: GlobeNewswire
SEATTLE, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it has commenced patient dosing in a Phase 2 clinical evaluation of otlertuzumab in a new indication – peripheral T-cell lymphoma (PTCL).  Otlertuzumab is a monospecific antibody targeting CD37 that was built on Aptevo’s ADAPTIR™ modular protein therapeutic platform. “Clinical proof-of-concept data from a randomized Phase 2 study demonstrated the efficacy and tolerability of otlertuzumab with bendamustine in relapsed chronic lymphocytic lymphoma (CLL).  In this study there was a significant increase in median progression free survival, from approximately 10 to 16 months in patients receiving the combination of otlertuzumab and bendamustine,” said Scott Stromatt, M.D., Senior Vice President and Chief Medical Officer for Aptevo.  “We were intrigued by recent reports in the literature showing Show less Read more
Impact Snapshot
Event Time:
APVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
APVO alerts

from News Quantified
Opt-in for
APVO alerts

from News Quantified